Sugi Predict

Sugi Predict / Compounds / SCHEMBL216810

SCHEMBL216810

SCHEMBL216810

CC(C)(C)OC(=O)N1CCN(c2ccc([N+](=O)[O-])c(N)c2)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.67
▸ LMNA P02545 3/20 0.67
▸ ALDH1A1 P00352 3/20 0.67
▸ SIRT6 Q8N6T7 3/20 0.62
▸ RECQL P46063 1/20 0.55
▸ MET P08581 1/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ PDK2 Q15119 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ SMARCA2 P51531 1/20 0.46
▸ SMARCA4 P51532 1/20 0.46
▸ PBRM1 Q86U86 1/20 0.46
▸ GPR119 Q8TDV5 4/20 0.46
▸ NAMPT P43490 1/20 0.45
▸ KCNH2 Q12809 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30565934 1.00 MAPT (0.67) MAPTLMNAALDH1A1SIRT6RECQL
SCHEMBL13548454 0.96 MAPT (0.61) MAPTLMNAALDH1A1SIRT6RECQL
SCHEMBL16270621 0.91 MAPT (0.70) MAPTLMNAALDH1A1SIRT6MET
SCHEMBL16270620 0.89 MAPT (0.71) MAPTLMNAALDH1A1SIRT6MET
SCHEMBL29858317 0.89 MAPT (0.71) MAPTLMNAALDH1A1SIRT6MET
SCHEMBL29600822 0.88 MAPT (0.61) MAPTLMNAALDH1A1SIRT6RECQL
SCHEMBL26911954 0.88 MAPT (0.61) MAPTLMNAALDH1A1SIRT6RECQL
SCHEMBL214341 0.87 MAPT (0.68) MAPTLMNAALDH1A1SIRT6MET
SCHEMBL29803559 0.87 MAPT (0.68) MAPTLMNAALDH1A1SIRT6MET
SCHEMBL1106913 0.87 MAPT (0.68) MAPTLMNAALDH1A1SIRT6MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4712974-A2 STAT DEGRADERS AND USES THEREOF Recludix Pharma, Inc. (US) 2026-03-25 — — EP disclosed
EP-4709370-A2 STAT DEGRADERS AND USES THEREOF Recludix Pharma, Inc. (US) 2026-03-18 — — EP disclosed
WO-2024238598-A2 STAT DEGRADERS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2024-11-21 — — WO disclosed
WO-2024238603-A2 STAT DEGRADERS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2024-11-21 — — WO disclosed
WO-2024233639-A2 STAT DEGRADERS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2024-11-14 — — WO disclosed
CN-117886798-A Substituted benzimidazoles and use thereof 河南中医药大学 2024-04-16 — — CN disclosed
CN-113214287-B HPK1 inhibitors and methods of use thereof 大学健康网络 2023-10-20 — — CN disclosed
US-11548875-B2 Inhibitor compounds for male contraception UNIVERSITY OF WASHINGTON (US) 2023-01-10 — — US disclosed
US-20220133713-A1 SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE Temple University--of the Commonwealth System of Higher Education 2022-05-05 — — US disclosed
US-20220133713-A1 SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE Temple University--of the Commonwealth System of Higher Education 2022-05-05 — — US disclosed
CN-101048382-A Novel Indole or Benzimidazole Derivatives HOFFMANN LA ROCHE (CH) 2007-10-03 — — CN disclosed
CN-1329382-C Novel arylsusfonamide compounds for treatment of obesity, type II diabetes and CNS-disorders BIOVITRUM AB (SE) 2007-08-01 — — CN disclosed
EP-1807398-A1 NEW INDOLE OR BENZIMIDAZOLE DERIVATIVES F. Hoffmann-Roche AG (CH) 2007-07-18 — — EP disclosed
US-7173035-B2 Arylsulfonamide compounds BIOVITRUM AB (SE) 2007-02-06 — — US disclosed
WO-2006045478-A1 NEW INDOLE OR BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-05-04 — — WO disclosed
US-20060089367-A1 New indole or benzimidazole derivatives as CB1 inverse agonists F. HOFFMANN-LA ROCHE AG (CH) 2006-04-27 — — US disclosed
CN-1531531-A Novel arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders �Ȱ�ά����ķ�ɷݹ�˾ 2004-09-22 — — CN disclosed
EP-0885213-A4 FIBRINOGEN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 1999-04-28 — — EP disclosed
EP-0885213-A1 FIBRINOGEN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1998-12-23 — — EP disclosed
WO-1997025323-A1 FIBRINOGEN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-07-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089367-A1 New indole or benzimidazole derivatives as CB1 inverse agonists CNR1, CNR2, GPR119 MAPT 2931/4885LMNA 4172/4885ALDH1A1 1339/4885
US-20220133713-A1 SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE SIGMAR1, TMEM97, OPRL1 MAPT 878/4885LMNA 2368/4885ALDH1A1 2183/4885
US-11548875-B2 Inhibitor compounds for male contraception ALDH1A1, ALDH3A1, ALDH16A1 MAPT 4083/4885LMNA 1751/4885ALDH1A1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.